Copyright
©The Author(s) 2023.
World J Diabetes. Apr 15, 2023; 14(4): 435-446
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.435
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.435
Table 1 General sample characteristics
Variable, n = 80 | Sex | Descriptive statistics | Mann-Whitney U test | ||||
Valid (n) | Mean | Minimum | Maximum | SD | Pvalue | ||
Age (yr) | Female | 39 | 69.00 | 45.00 | 80.00 | 6.27 | 0.151516 |
Male | 41 | 65.32 | 37.00 | 76.00 | 9.56 | ||
Weight (kg) | Female | 39 | 77.36 | 54.00 | 108.00 | 12.24 | 2.55E-03 |
Male | 41 | 88.66 | 63.00 | 150.00 | 16.52 | ||
Height (cm) | Female | 39 | 161.38 | 150.00 | 174.00 | 5.97 | 1.78E-11 |
Male | 41 | 175.15 | 164.00 | 190.00 | 6.90 | ||
BMI (kg/m2) | Female | 39 | 29.68 | 21.90 | 40.20 | 4.52 | 2.64E-01 |
Male | 41 | 28.84 | 21.50 | 44.30 | 4.90 | ||
HbA1c (%) | Female | 38 | 6.42 | 5.20 | 8.50 | 0.79 | 4.87E-01 |
Male | 40 | 6.58 | 5.00 | 8.80 | 0.97 | ||
DM1 duration (yr) | Female | 39 | 12.10 | 0.00 | 37.00 | 8.13 | 2.90E-01 |
Table 2 Reliability results for the patient and practitioner sections of the Michigan Neuropathy Screening Instrument-Polish version
Part A of MNSI | Part B of MNSI | |||
n = 80 | Cronbach alpha, full scale: 0.81790 | Cronbach alpha, full scale: 0.87095 | ||
Corr 1st & 2nd half: 0.745791 | Corr 1st & 2nd half: 0.972206 | |||
Split-half reliability: 0.854388 | Split-half reliability: 0.985907 | |||
Guttman split-half: 0.840785 | Guttman split-half: 0.985838 | |||
Summary for A1 | Summary for A2 | Summary for B1 | Summary for B2 | |
Mean | 4.250000 | 4.150000 | 6.212500 | 6.175000 |
Sum | 340.0000 | 332.0000 | 497.0000 | 494.0000 |
SD | 3.403275 | 4.313946 | 3.925553 | 3.860790 |
Variance | 11.58228 | 18.61013 | 15.40997 | 14.90570 |
Cronbach alpha | 0.6499672 | 0.7060083 | 0.7337023 | 0.7346509 |
Table 3 Stability of the patient and practitioner sections of the Michigan Neuropathy Screening Instrument-Polish version
Part of MNSI | Mean (SD) | ICC for agreement | ICC for consistency | |||
Test score | Re-test score | ICCagreement | Pvalue | ICCconsistency | Pvalue | |
A | 2.125 (1.70) | 2.075 (2.16) | 0.728 | 9.05E-15 | 0.725 | 9.47E-15 |
B | 3.106 (1.96) | 3.088 (1.93) | 0.972 | 6.19E-52 | 0.972 | 8.53E-52 |
Table 4 The area under the curve values for Nerve Conduction Study and Michigan Neuropathy Screening Instrument Polish version (version A and B) at both time points
Variable | AUC | Pvalue |
A1 | 0.749 | 0.0003 |
B1 | 0.796 | 0.0000 |
A2 | 0.617 | 0.2296 |
B2 | 0.770 | 0.0001 |
Table 5 The cut-off points for Michigan Neuropathy Screening Instrument Polish version at the two time points and their sensitivity and specificity, and their positive and negative predictive values based on receiver operating characteristic curves
Variable | True positives, n, % | False positives, n, % | False negatives, n, % | True negatives, n, % | Sensitivity | Specificity | Optimal cut-off point |
A1 | 28/35 | 0/0 | 42/52.5 | 10/12.5 | 0.400 | 1.000 | 3 |
B1 | 57/71.25 | 3/3.75 | 13/16.25 | 7/8.75 | 0.814 | 0.700 | 2 |
A2 | 23/28.75 | 1/1.25 | 47/58.75 | 9/11.25 | 0.329 | 0.900 | 3 |
B2 | 59/73.75 | 4/5 | 11/13.75 | 6/7.5 | 0.843 | 0.600 | 2 |
- Citation: Sutkowska E, Marciniak D, Koszewicz M, Dziadkowiak E, Budrewicz S, Biernat K, Kuciel N, Mazurek J, Hap K. Validity and reliability of the Polish version of the Michigan Neuropathy Screening Instrument. World J Diabetes 2023; 14(4): 435-446
- URL: https://www.wjgnet.com/1948-9358/full/v14/i4/435.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i4.435